Drug Profile
XEN 403
Alternative Names: XEN-403Latest Information Update: 23 Aug 2021
Price :
$50
*
At a glance
- Originator Xenon Pharmaceuticals
- Class Non-opioid analgesics
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 23 Aug 2021 Discontinued - Phase-I for Pain in Canada (PO) (Xenon pipeline, August 2021)
- 15 Mar 2012 Phase-I clinical trials in Pain ongoing in Canada (PO)
- 08 Feb 2011 Phase-I clinical trials in Pain in Canada (PO)